Global Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Pipeline Review 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Pipeline Review, H1 2016" report to their offering.

'Complement C5 - Pipeline Review, H1 2016'; Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) pipeline Target constitutes close to 24 molecules. Out of which approximately 21 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says; Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Complement component 5 is a protein is encoded by the C5 gene. Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.

Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

The report 'Complement C5 - Pipeline Review, H1 2016' outlays comprehensive information on the Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 6, 3 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Companies Mentioned

  • Akari Therapeutics, Plc
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Epirus Biopharmaceuticals, Inc.
  • InflaRx GmbH
  • Novartis AG
  • Noxxon Pharma AG
  • Ophthotech Corp.
  • Ra Pharmaceuticals, Inc.
  • Swedish Orphan Biovitrum AB

For more information visit http://www.researchandmarkets.com/research/n45t48/complement_c5_c3

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals